LKLidiya A. Klyukina

Lidiya A. Klyukina

*This is an algorithmically generated author record based on publicly available information.

Lidiya A. Klyukina has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hormonal optimization of ovarian function in women of advanced reproductive age with diminished ovarian reserve

    by Lidiya A. Klyukina, Elena A. Sosnova, Igor I. Guzov, Клюкина Лидия Александровна

    BACKGROUND: In reproductive medicine, diminished ovarian reserve remains a pressing challenge, particularly in the search for effective strategies to address it. Surgical methods for ovarian activation are actively being investigated, along with ongoing research into hormonal therapies. In this context, researchers worldwide have focused on the potential application of dehydroepiandrosterone (DHEA) to improve ovarian reserve in women of advanced reproductive age who are planning pregnancy. AIM: To evaluate the effects of DHEA administration on hormonal profile changes and ovarian reserve parameters in women of advanced reproductive age with diminished ovarian reserve, as well as to assess pregnancy and live birth rates in this population. METHODS: The study included 118 women of advanced reproductive age diagnosed with diminished ovarian reserve. All participants underwent hormonal evaluation on days 2–3 of the menstrual cycle, including measurements of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, prolactin, anti-Müllerian hormone (AMH), and inhibin B, as well as folliculometry. The participants were then prescribed DHEA at 75 mg/day, with follow-up hormonal evaluation at 3, 6, and 8 months, along with repeated folliculometry. After treatment completion, data were analyzed, and pregnancy rates were evaluated. RESULTS: DHEA administration at 75 mg/day for 8 months was associated with a significant reduction in gonadotropin levels (FSH: 9.91 [8.60; 10.90], LH: 7.63 [6.40; 8.60]) and an elevation in estradiol levels (90.22 [78.90; 107.60]; p 0.001). A significant improvement in ovarian reserve parameters was observed, as evidenced by changes in laboratory markers (AMH: 1.08 [0.76; 1.40], inhibin B: 98.38 [88.60; 111.40]; p 0.001) and ultrasound folliculometry findings, which demonstrated an increase in antral follicle count to 6–7. A significant reduction in the frequency of menstrual cycle irregularities was observed, with the incidence decreasing to 29.2% (26/118). Pregnancy occurred in 31.3% of women (37/118), with spontaneous conception in 62.1% (23/37) and conception achieved via in vitro fertilization in 37.8% (14/37). A live birth rate of 70.2% (26/37) was recorded, whereas 29.7% (11/37) of pregnancies ended in spontaneous miscarriage. CONCLUSION: DHEA administration at 75 mg/day for 8 months in women of advanced reproductive age with diminished ovarian reserve is associated with improvements in ovarian reserve parameters and an increased likelihood of achieving a desired pregnancy.

  • Open Access

    The possibilities of predicting the individual risk of cervical cancer in women of reproductive age using mathematical modeling

    by L. A. Klyukina, E. A. Sosnova, A. A. Ishchenko, M. M. Davydov

    Background. Cervical cancer (CC) refers to cancer of visual localization and in women of reproductive age remains one of the most common oncological diseases. The carcinogenesis of CC is caused by the persistence of highly oncogenic types of human papillomavirus (HPV), the level of carcinogenicity of which is the highest based on the criteria of the International Agency for Research on Cancer. However, cervical carcinogenesis does not occur in all cases of persistence of highly oncogenic types of HPV. This, in turn, determines the need for a thorough search, study and analysis of possible cofactors that can lead to neoplastic changes in the cervix.Aim. To develop a model for predicting the individual risk of CC in women of reproductive age, taking into account clinical, anamnestic, laboratory and histological data.Materials and methods. The material for the study was retrospective examination data from 251 patients of reproductive age who were treated at the Center for Gynecology and Reproductive Technologies of the National Medical Research Center “Medical and Rehabilitation Center”, Ministry of Health of Russia in the period 2015–2022. Results. Highly oncogenic HPV types were significantly more common in the group of patients with verified СС who took combined oral contraceptives (COC), compared with patients who did not take COC (p = 0.035). Multifactorial analysis allowed us to determine that long-term use of СОС for a total of more than 7 years is associated with a tendency to increase the risk of developing СС (hazard ratio 1.68; 95 % confidence interval 1.1–2.5; p = 0.010). According to the results of statistical calculation, the values of regression coefficients were obtained and the tendency to increase the risk of developing CC was predicted in the presence of such factors as: HPV type 16 persistence, body mass index, and the duration of COC intake in years.Conclusion. Thus, taking into account all possible risk factors for CC, the negative effect of cofactors, namely increased body mass index and prolonged intake of COC, on the course of HPV as the leading etiological factor of breast cancer, will allow us to identify groups at increased risk of developing CC, form an individual algorithm for monitoring and examination throughout the entire period of taking COC, as well as conduct individual cancer prevention by limiting the duration of taking COC.


  • Open Access

    Debate on the oncologic potential of sex steroid preparations

    by Lidiya A. Klyukina, Elena A. Sosnova, Anton A. Ishchenko, Mikhail M. Davydov, Клюкина Лидия Александровна

    Background. Thanks to numerous worldwide studies, the significant contribution of the hormonal component to the oncological risks of the organs of the female reproductive system is beyond doubt. Of great interest is the analysis of world research on the oncological potential of hormonal drugs, namely COCs and MGT, since this issue continues to be one of the most complex and controversial. Aim. This study aimed to contribution of hormonal factors to the development of cancer of the female reproductive system, namely breast, cervical, endometrial and ovarian cancers. Materials and Methods. The study was conducted on the basis of the Center of Gynecology and Reproductive Technologies of the FSAU “National Medical Research Center “Treatment and Rehabilitation Center” of the Ministry of Health of the Russian Federation, the Department of Oncogynecology of the University Clinical Hospital No. 4 of the I.M. Sechenov First Moscow State Medical University. The analysis of medical documentation for the period from January 2015 to December 2021 was carried out. The study included 1842 patients with verified oncological disease of the female reproductive system, who had a history of taking hormonal drugs of the following pharmacological groups: hormonal contraceptives, menopausal hormone therapy drugs. The age of all patients ranged from 26 to 83 years (mean age 51.98±10.3 years). The control group consisted of 611 patients without oncological diseases, who have a history of indications for taking hormonal drugs of these pharmacological groups. Results. When assessing the effect of the duration of MGT intake on the risk of developing breast cancer, it was found that MGT intake for a total of more than 6 years was associated with a higher risk of developing breast cancer (HR 1.18; CI 1.02–1.36; p 0.001). Using the Wald method, we found that the probability of developing breast cancer is associated with a BMI of more than 25 kg/m2 and long-term intake of combined MGT for a total of more than 6 years. When assessing the effect of the duration of MGT intake on the risk of developing RTM, it was found that MGT intake for a total of more than 6 years was associated with a higher risk of developing RTM (HR 1,432; CI 1,172–1,750; p 0.001). Using the Wald method, we found that the probability of developing RTM is associated with the presence of a BMI of more than 25 kg/m2, prolonged MGT intake for a total of more than 6 years and the presence of endometrial hyperplastic processes, adenomyosis, hypertension in the anamnesis. When assessing the effect of the duration of COC intake on the risk of developing breast cancer, it was found that taking COC for a total of more than 7 years was associated with a higher risk of developing breast cancer (HR 1.68; CI 1.1–2.5; p=0.010). According to the Wald method, it was revealed that the probability of developing breast cancer is associated with the presence of HPV type 16, a BMI of more than 25 kg/m2 and prolonged intake of COCs for a total of more than 7 years. When assessing the effect of the duration of MGT intake on the risk of developing PC, it was found that MGT intake for a total of more than 9 years was associated with a higher risk of developing PC (HR 1.65; CI 1.2–2.3; p=0.010). Using the Wald method, we found that the probability of developing RYA is associated with the presence of a BMI of more than 25 kg/m2, MGT intake and the presence of endometrial hyperplastic processes in the anamnesis. Conclusions. With prolonged use of sex steroids, there is a tendency to increase the risk of developing cancer of the female reproductive system. Careful follow-up and limitation of the duration of taking sex steroids in risk groups will reduce carcinogenic risks.

  • Open Access

    Cervical carcinogenesis associated with the use of combined oral contraceptives: is there a relationship?

    by Lidiya A. Klyukina, Elena A. Sosnova, Anton A. Ishchenko, Mikhail M. Davydov, Клюкина Лидия Александровна

    BACKGROUND: Cervical cancer is one of the leading cancers in women of reproductive age. The etiological role of the human papillomavirus (HPV) in cancer development is long known and undisputed. However, owing to the widespread use of combined oral contraceptives (COCs), scientists actively investigate possible mechanisms of interrelation between sex steroids and HPV in terms of cervical cancer risk. AIM: This study aimed to assess the risk of cervical cancer in women of reproductive age, depending on the use of COCs for different durations. MATERIALS AND METHODS: The study included 411 patients of reproductive age who were treated at the Center for Gynecology and Reproductive Technologies of the Russian Ministry of Health and the Department of Oncogynecology at the University Clinical Hospital No. 4 of the I.M. Sechenov First Moscow State Medical University between January 2015 and December 2021. All patients were divided into two groups. The study group included 291 patients with verified cervical cancer, and the control group included 120 patients without cancer. RESULTS: The study group was significantly more likely to take COCs (56, or 19.2%) than the control group (11, or 6.5%; p=0.018). In addition, the study group had significantly longer treatment durations (p=0.011). Overweight (n = 52, or 17.9%) and grade II obesity (n = 11, or 3.8%, vs. 0; p=0.03) were significantly more common in the study group than in the control group (n = 8, or 4.7%; p=0.003). The result of the multivariate analysis showed that taking COCs negatively affect cervical cancer development (p=0.018; odds ratio (OR) 1.230; CI 1.064–1.423). The receiver operating characteristic analysis revealed that the use of COCs has a high predictive value for determining the risk of cervical cancer (area under the curve, AUC=0.742); the sensitivity and specificity of this predictor were 74.07% and 72.73%, respectively. In the assessment on the effect of duration of COC use on the risk of cervical cancer, the results showed that total use of COCs for over 7 years was associated with a higher risk of cervical cancer development (p=0.010; OR 1.68; CI 1.1–2.5). CONCLUSIONS: Prescribing COCs in patients with HPV infection requires a personalized approach to consider etiologic factors of cervical cancer and reduce possible carcinogenic risks.


  • Open Access

    Phenomenon of hormone-dependent polyneoplasia of the female reproductive system

    by Lidiya A. Klyukina, Elena A. Sosnova, Anton A. Ishchenko, Mikhail M. Davydov, Клюкина Лидия Александровна

    BACKGROUND: Primary multiplicity of malignant tumors of the female reproductive system is the least studied area of clinical oncology. In addition, the steady rise in the number of patients and various localizations of polyneoplasia with lesions of the female reproductive organs necessitate a detailed study of this problem. AIM: This study aimed to determine the incidence and risk factors and describe the clinical aspects of polyneoplasia of the female reproductive system for 20102021 in women seen at the Medical and Rehabilitation Center of the Ministry of Health of Russia, Moscow, and the University Clinical Hospital No. 4 of the I.M. Sechenov First Moscow State Medical University. MATERIALS AND METHODS: We conducted a retrospective analysis of the case records of 147 patients with a confirmed diagnosis of polyneoplasia of the female reproductive system for 20102021, which accounted for 3.6% of all newly diagnosed neoplasms of the female reproductive system in the above medical institutions. Moreover, a continuous sampling method was used. RESULTS: Breast cancer was the most frequent first tumor, combined with cancer of the contralateral breast in 27 (42.1%) patients, cancer of the uterine body in 4 (6.25%) patients, ovarian cancer in 4 (6.25%) patients, colon cancer in 4 (6.25%) patients, and thyroid cancer in 1 (1.5%) patient. Cancer of the uterine body was combined with breast cancer in 10 (35.7%) patients, ovarian cancer in 2 (7.1%) patients, thyroid cancer in 2 (7.1%) patients, and colon cancer in 3 (11.1%) patients. Endometrioid adenocarcinoma, pathogenic variant I was determined in 20 (71.4%) cases according to the histological structure. Thyroid cancer was detected in 7 (5.6%) cases; in all cases, it developed metachronously, and it was combined as the initial tumor with breast cancer in 1 (14.3%) case, uterine body cancer in 2 (28.5%) cases, and ovarian cancer in 1 (14.3%) case. As the second tumor, it was also combined with uterine body cancer in 2 (28.5%) cases and ovarian cancer in 1 (14.3%) case. The risk factors assessment led to the identification of several factors that are common in patients with hormone-dependent forms of primary multiple cancer, including obesity, diabetes mellitus, irregular menstrual cycle, history of proliferative diseases of the mammary glands, intake of thyroid drugs, uterine hyperplastic processes, and hypothyroidism. CONCLUSIONS: Understanding the different aspects of the development and course of hormone-dependent polyneoplasia of the female reproductive system will help in developing approaches for follow-up monitoring of women who have been treated for a primary tumor and are at risk of developing a subsequent tumor of hormone-dependent organs, to prevent the recurrence of the disease and predict the subsequent tumor and ensure its timely detection.

  • Open Access

    Photodynamic therapy and cervical intraepithelial neoplasia: current achievements and development prospects

    by I. V. Reshetov, E. A. Sosnova, A. L. Unanyan, A. A. Ishchenko, L. A. Klyukina

    Photodynamic therapy and cervical intraepithelial neoplasia: current achievements and development prospects


  • Open Access

    Assisted reproductive technology and uterine cancer risk. A systematic review and meta-analysis

    by Lidia A. Klyukina, Elena A. Sosnova, Anton А. Ishchenko, Клюкина Лидия Александровна

    BACKGROUND: The problem of infertility has not only medical, but also socio-demographic significance. To date, the global scale of the spread of various forms of infertility is beyond doubt among specialists around the world. This, in turn, causes an increase in the frequency of prescribing assisted reproductive technologies, but the question of the relationship between the prescribing of drugs used to treat infertility and the risk of developing cancer of the uterine body remains poorly understood. AIM: The aim of this study was to assess the possible relationship between in vitro fertilization, the use of ovulation stimulation drugs and the risk of developing uterine cancer in women with infertility. MATERIALS AND METHODS: This literature systematic review is based on resources from the following databases: Medline, ClinicalKey, Google Scholar, Embase, the Cochrane Library, and eLIBRARY for the period 19992022. The search for publications was carried out using keywords defined in accordance with the PICO principle (P, population or patients; I, intervention; C, comparison; O, outcomes): female, women, infertility, infertility treatment, in vitro fertilization, IVF, assisted reproductive technology, ART, ovarian stimulation, ovarian hyperstimulation, clomiphene citrate, hCG, hMG, tamoxifen, uterine, endometrial, cancer, carcinoma neoplasm, uterine neoplasm. The following SQL operators were used during the search: AND and OR. RESULTS: The search resulted in 37 representative publications, with eight studies selected for meta-analysis. CONCLUSIONS: This systematic review and meta-analysis have demonstrated the ambiguity of the design and results of studies on the possible relationship of uterine cancer and assisted reproductive technology methods published to date. The issue under review is urgent due to the high frequency of infertility and an increase in the frequency of gynecologic cancers. The conducted studies confirm that it is impossible to evaluate the carcinogenic effect of ovulation inducers or in vitro fertilization methods without adjusting for the infertility factor, as well as risk factors for uterine cancer. There is still a high need for further research, particularly for studying the safety profile of infertility treatment methods in relation to long-term cancer risks.

  • Open Access

    The stimulation of ovulation and endometrial carcinogenesis: possible relationship and study prospects (literature review)

    by Lidiya A. Klyukina, Elena A. Sosnova, Anton A. Ishchenko, Клюкина Лидия Александровна

    Currently, infertility is still a global problem; therefore, reproductive doctors worldwide are actively studying new and improving existing methods of overcoming female infertility. In recent years, the arsenal of drugs that can stimulate ovarian function has significantly expanded. A prerequisite for the use of drugs in this group is the presence of a follicular apparatus in the ovaries. Ovulation inducers contribute to the maturation of several follicles at once, and their ability to influence the process of steroidogenesis is beyond doubt. However, the long-term risk assessment when using these drugs, namely the risk of developing malignant female reproductive system neoplasm, remains poorly understood despite their long-term use. This problem is multifaceted and quite difficult to study since the etiological causes of infertility are considered a risk factor for developing malignant female reproductive system neoplasms. Oncological diseases are diagnosed several years after infertility treatment, thus proving a causal relationship is difficult, on the one hand, and dictating the need for a long period of observation in the group of women who underwent infertility treatment, considering the characteristics of each specific method, on the other hand. Herein, the authors analyzed the results of published studies on the possible relationship between ovulation induction and the risk of developing cancer in the uterine body.

  • Carcinogenic Potential Of Ovulation Stimulation In BRCA1/2 Gene Mutation Carriers In Assisted Reproductive Technology Programs

    by Lidia A. Klyukina, Elena A. Sosnova, Anton A. Ishchenko

    Mutations of the BRCA1/2 genes constitute a fundamental and independent risk factor in the genesis of both breast cancer and ovarian cancer. The specifics of the infertility treatment effect on the risk of developing cancer in carriers of mutations in the BRCA1/2 genes remain unclear and require a comprehensive investigation. In this review, we analyzed published sources on the possible relationship between the infertility treatment and the risk of ovarian and breast cancer in BRCA1/2 mutation carriers.